There are currently 26 clinical trials in Cypress, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including studies in Dermatology, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/22/2025
Locations: Research Site, Cypress, Texas
Conditions: Acute Coronary Syndrome
Register for Updates
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
NCT06822517
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
04/21/2025
Locations: Investigative Site, Cypress, Texas
Conditions: Parkinson Disease
Register for Updates
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Cypress Heart and Vascular Center, Cypress, Texas
Conditions: Chronic Heart Failure
Register for Updates
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
NCT06873516
Recruiting
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Studies in Dermatology, Cypress, Texas
Conditions: Chronic Spontaneous Urticaria
Register for Updates
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
04/09/2025
Locations: Pioneer Research Solutions, Inc., Cypress, Texas
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/02/2025
Locations: Studies in Dermatology LLC, Cypress, Texas
Conditions: Plaque Psoriasis
Register for Updates
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
NCT06625398
Recruiting
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Horizon Clinical Research Group, Cypress, Texas
Conditions: Thyroid Eye Disease
Register for Updates
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840566, Cypress, Texas
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/25/2025
Locations: Horizon Clinical Research Group, Cypress, Texas
Conditions: Parkinson Disease
Register for Updates
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386
Recruiting
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: GSK Investigational Site, Cypress, Texas
Conditions: Asthma
Register for Updates
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT04173273
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2025
Locations: Houston Pulmonary Sleep and Allergy Associates (PFT), Cypress, Texas
Conditions: Crohn's Disease
Register for Updates
Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.
NCT06600152
Recruiting
A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
09/30/2024
Locations: Studies in Dermatology, Cypress, Texas
Conditions: Wound Heal
Register for Updates